Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics Inc.

Dianthus Therapeutics, Inc. ($DNTH) announced an update on their ongoing clinical study. Dianthus Therapeutics, Inc. is running a Phase 3 study cal...

Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akari Therapeutics (AKTX) and Dianthus Therapeutics ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNTH	$104.09	+2.40%	887.30K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNTH	$104.09	+2.4%	887.30K
3
4
5
6

DNTH

DNTH

Get Dianthus Therapeutics Inc. Data in Excel

Get Dianthus Therapeutics Inc. Data in Excel